Mineralys Therapeutics
Biopharmaceuticals
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing medicines to target hypertension and related comorbidities including chronic kidney disease (CKD) and obstructive sleep apnea (OSA), particularly diseases driven by dysregulated aldosterone. Its initial product candidate lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor, and the company is pursuing a commercial launch of its first product with roles focused on educating healthcare providers and driving adoption in assigned territories. The company is headquartered in Radnor, Pennsylvania and is described as fully remote.
11-50 employeesRadnor, PennsylvaniaFounded 2020